Researchers performed a meta-analysis in order to examine the safety of lowering LDL-C to very low levels using the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab.
In a recent expert-led presentation at the Practial Updates in Primary Care Virtual Series, Seth S. Martin, MD, MHS, and Daniel E. Soffer, MD, reviewed current evidence and clinical strategies for using...
